Eurofins Scientific SE (ERFSF) Stock Analysis

Eurofins Scientific SE (ERFSF) Healthcare & Pipeline Overview

Eurofins Scientific SE is a global leader in analytical testing and laboratory services, providing a comprehensive suite of solutions across diverse sectors, including food, environment, pharmaceuticals, and consumer products. The company's extensive network and scientific expertise position it as a key player in ensuring safety and quality standards worldwide.

What Is the Investment Thesis for ERFSF?

With a market capitalization of $14.3B, the company benefits from a stable revenue stream driven by regulatory requirements and increasing consumer demand for safety and quality. A gross margin of 22.5% and an ROE of 9.5% indicate solid profitability. Ongoing: The company's strategic acquisitions and expansion into high-growth areas such as biopharma and environmental testing are expected to drive future revenue growth. However, a debt-to-equity ratio of 96.84 and a beta of 0.94 suggest moderate financial risk and market sensitivity.

Based on FMP financials and quantitative analysis

ERFSF Key Highlights

Market capitalization of $14.3B reflects its significant presence in the analytical testing market.

• Profit margin of 6.5% indicates moderate profitability within the competitive diagnostics and research sector.
• Gross margin of 22.5% demonstrates the company's ability to generate revenue above the cost of goods sold.
• Return on Equity (ROE) of 9.5% suggests efficient utilization of shareholder equity to generate profits.
• Debt-to-Equity ratio of 96.84 indicates a relatively high level of financial leverage.

Who Are ERFSF's Competitors?

What Are ERFSF's Key Strengths?

Global presence with an extensive network of laboratories.

• Diversified service offerings across multiple industries.
• Strong reputation for scientific expertise and quality.
• Proven track record of strategic acquisitions and growth.

What Are ERFSF's Weaknesses?

High debt-to-equity ratio.

• Exposure to regulatory changes and compliance risks.
• Dependence on acquisitions for growth.
• Potential for price competition in certain markets.

What Could Drive ERFSF Stock Higher?

Expansion of biopharma testing services to capitalize on the growing biopharmaceutical industry.

• Strategic acquisitions to expand service offerings and geographic reach.
• Increasing focus on environmental testing to meet growing demand for environmental monitoring.
• Leveraging technological advancements to improve efficiency and accuracy of testing processes.

What Are the Key Risks for ERFSF?

High debt-to-equity ratio could limit financial flexibility.

• Changes in regulatory requirements and compliance standards could increase costs.
• Economic downturns could reduce spending on testing services.
• Intense competition from other testing laboratories could put pressure on pricing.
• Product liability claims and recalls could damage reputation and financial performance.

What Are the Growth Opportunities for ERFSF?

• Expansion in Biopharma Testing: The biopharmaceutical industry is experiencing rapid growth, driven by the development of novel therapies and increasing regulatory scrutiny. Eurofins can capitalize on this trend by expanding its biopharma testing services, including drug discovery, clinical trials, and quality control. The global biopharmaceutical testing market is projected to reach $120 billion by 2027, offering significant growth potential for Eurofins. Timeline: Ongoing.
• Increasing Focus on Environmental Testing: Growing concerns about environmental pollution and climate change are driving demand for environmental testing services. Eurofins can leverage its expertise in water, air, and soil testing to capture a larger share of this market. The global environmental testing market is expected to reach $35 billion by 2026, presenting a substantial opportunity for Eurofins. Timeline: Ongoing.
• Growth in Food Safety Testing: With increasing consumer awareness of food safety and stricter regulations, the demand for food testing services is growing. Eurofins can expand its food testing capabilities, including allergen testing, GMO testing, and pesticide residue testing, to meet this demand. Timeline: Ongoing.
• Penetration of Emerging Markets: Emerging markets, such as China, India, and Brazil, are experiencing rapid economic growth and increasing demand for testing and analytical services. Eurofins can expand its presence in these markets through strategic acquisitions and partnerships. The growth in these regions offers substantial opportunities for Eurofins to increase its global market share. Timeline: Ongoing.
• Strategic Acquisitions: Eurofins has a history of growth through strategic acquisitions. By acquiring smaller testing laboratories and specialized service providers, Eurofins can expand its service offerings, geographic reach, and customer base. This strategy allows Eurofins to quickly enter new markets and gain access to specialized expertise. Timeline: Ongoing.

What Opportunities Does ERFSF Have?

• Expansion in high-growth areas such as biopharma and environmental testing.
• Penetration of emerging markets with increasing demand for testing services.
• Leveraging technological advancements to improve efficiency and accuracy.
• Increasing outsourcing of testing services by large corporations.

What Are ERFSF's Competitive Advantages?

• Extensive network of laboratories across the globe.
• Wide range of testing services across various industries.
• Strong reputation for scientific excellence and customer service.
• Strategic acquisitions to expand service offerings and geographic reach.

What Does ERFSF Do?

Founded in 1987 and headquartered in Luxembourg, Eurofins Scientific SE has grown from a small food testing laboratory to a global leader in analytical testing and laboratory services. The company's initial focus on food authenticity testing has expanded significantly to encompass a wide range of industries, including pharmaceuticals, environmental science, agriculture, and consumer products. Eurofins provides services such as agroscience, biopharma, clinical diagnostics, and consumer product testing. Its offerings include biological assessment, consumer and human safety testing, product chemistry, regulatory consultancy, and seed services. The company also provides assurance services, including sustainability audits, certification, quality inspection, and food and dietary supplement labeling. Eurofins operates a network of laboratories across the globe, providing testing services for water, air, soil, building materials, and waste. It also offers specialized testing services such as forensic, genomic, maritime, materials and engineering, and sensory and consumer services. Eurofins' commitment to scientific excellence and customer service has driven its growth, making it a trusted partner for businesses seeking to ensure the safety, quality, and compliance of their products and processes.

What Products and Services Does ERFSF Offer?

• Provides analytical testing services for food, environment, pharmaceutical, and consumer products.
• Offers laboratory services, including water, air, and soil testing.
• Conducts biological assessments and product chemistry testing.
• Provides regulatory consultancy and seed services.
• Offers sustainability audits, certification, and quality inspection services.
• Provides clinical diagnostics and biopharma testing services.
• Offers forensic, genomic, maritime, materials and engineering, REACH, and sensory and consumer services.

How Does ERFSF Make Money?

• Generates revenue by providing analytical testing and laboratory services to various industries.
• Offers a wide range of testing services, including food, environment, pharmaceutical, and consumer products.
• Operates a network of laboratories across the globe, providing testing services for water, air, soil, building materials, and waste.
• Acquires smaller testing laboratories and specialized service providers to expand its service offerings and geographic reach.

What Industry Does ERFSF Operate In?

Eurofins Scientific SE operates in the diagnostics and research industry, which is characterized by increasing demand for testing and analytical services driven by stringent regulatory requirements and growing consumer awareness of safety and quality. The global market for testing, inspection, and certification is projected to reach $250 billion by 2028, growing at a CAGR of 4.5%. Eurofins competes with companies such as SGS SA, Intertek Group, and Bureau Veritas, offering a wide range of testing services across various sectors. The industry is also influenced by technological advancements, such as automation and data analytics, which are improving the efficiency and accuracy of testing processes.

Who Are ERFSF's Key Customers?

• Food manufacturers and processors
• Pharmaceutical companies
• Environmental agencies and organizations
• Consumer product manufacturers
• Government agencies

Company Profile

Eurofins Scientific SE operates in the Medical - Diagnostics & Research industry within the Healthcare sector. It is headquartered in Luxembourg City, LU. The company is led by CEO Gilles G. Martin. ERFSF has traded publicly since 2010.

Return on equity for Eurofins Scientific SE stands at 14.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 4.8%, showing how much profit it generates from its asset base. ERFSF trades at a trailing price-to-earnings ratio of 23.79, above the Healthcare sector average of ~21.50x. Its free cash flow yield is 5.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.13 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 4.1%, the inverse of the P/E and a quick read on earnings relative to price.

ERFSF Valuation & Market Position

With a $14.3B market cap, Eurofins Scientific SE sits in the large-cap segment of the market.

Quarterly Financial Performance: Eurofins Scientific SE

Revenue for Eurofins Scientific SE came in at $4.29B during Q2 FY2026. The company recorded net income of $349.9M, with diluted EPS of $1.90. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this large-cap Healthcare company. Across the four most recent quarters, ERFSF averaged $1.49 in diluted EPS.

Eurofins Scientific SE's Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 3.27 places it in the safe zone, indicating low near-term bankruptcy risk.

Eurofins Scientific SE has beaten Wall Street's EPS estimate in 4 of its last 8 reported quarters — more hits than misses. Reported results have landed about 2.6% below estimates on average.

ERFSF Financials

ERFSF Latest News

ERFSF Analyst Consensus

ERFSF MoonshotScore

ERFSF Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources